Mirum Pharmaceuticals shares are up about 5.4% today as bullish analyst activity from late March continues to reverberate through the tape, with multiple firms reiterating positive ratings and lifting price targets. In the most recent cluster of updates, targets were raised into the mid-$120s and higher (e.g., TD Cowen to $125; other firms cited with targets around $126 and $132), supporting incremental buying as investors recalibrate upside expectations after the stock’s strong run. (ms.investing.com)

The bullish stance is rooted in Mirum’s rare-disease commercial base and the view that upcoming development milestones could add to the company’s growth profile beyond its existing franchise. Investor attention remains trained on a busy 2026 catalyst calendar across Mirum’s liver-disease pipeline, where positive data could expand the addressable market and reinforce long-term revenue expectations. (investing.com)

Near-term, the key question is whether the stock’s move sustains or fades as the market digests the recent analyst revisions and looks for the next fundamental trigger. Clinically, Mirum has highlighted that its EXPAND Phase 3 program completed enrollment, with topline data expected in Q4 2026—timing that can still influence positioning well ahead of readout windows in SMID-cap biotech. (simplywall.st)

Today’s gain looks primarily sentiment-driven—an analyst-target momentum bid rather than a single new regulatory or clinical headline. With targets clustered well above the current price and multiple 2026 milestones approaching, MIRM is likely to remain headline- and note-sensitive, with outsized moves possible on incremental updates. (ms.investing.com)